Andra AP fonden Takes $2.42 Million Position in Insulet Co. (NASDAQ:PODD)

Andra AP fonden acquired a new stake in Insulet Co. (NASDAQ:PODD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,000 shares of the medical instruments supplier’s stock, valued at approximately $2,422,000.

Other hedge funds also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. purchased a new position in Insulet during the 1st quarter valued at about $29,000. International Assets Investment Management LLC purchased a new position in Insulet during the second quarter valued at approximately $32,000. UMB Bank n.a. raised its stake in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares in the last quarter. Jones Financial Companies Lllp bought a new position in Insulet in the fourth quarter worth approximately $40,000. Finally, CVA Family Office LLC lifted its holdings in Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Redburn Atlantic assumed coverage on shares of Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 target price for the company. Barclays raised their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. BTIG Research reduced their price objective on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $234.00 target price on shares of Insulet in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $225.29.

Insulet Price Performance

NASDAQ PODD opened at $230.45 on Friday. The stock’s fifty day moving average price is $198.49 and its 200 day moving average price is $185.28. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $232.56. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The company has a market cap of $16.14 billion, a price-to-earnings ratio of 69.83, a PEG ratio of 4.02 and a beta of 1.21.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. Insulet’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.38 EPS. As a group, equities research analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.